The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study (Q34570826)

3 August 2017

The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study (English)

1 reference

3 August 2017

1 reference

M J Millward

1

1 reference

3 August 2017

C House

2

1 reference

3 August 2017

D Bowtell

3

1 reference

3 August 2017

L Webster

4

1 reference

3 August 2017

I N Olver

5

1 reference

3 August 2017

M Gore

6

1 reference

3 August 2017

M Copeman

7

1 reference

3 August 2017

K Lynch

8

1 reference

3 August 2017

A Yap

9

1 reference

3 August 2017

Y Wang

10

1 reference

3 August 2017

P S Cohen

11

1 reference

3 August 2017

J Zalcberg

12

1 reference

3 August 2017

language of work or name

English

0 references

publication date

12 September 2006

1 reference

British Journal of Cancer

3 August 2017

1 reference

3 August 2017

95

1 reference

3 August 2017

7

1 reference

3 August 2017

829-834

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603331

3 August 2017

0 references

cites work

Medical management of melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360547

Protein kinase C isoforms in normal and transformed cells of the melanocytic lineage.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360547

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360547

The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360547

Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360547

Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360547

The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360547

Differential inhibition of cytosolic and membrane-derived protein kinase C activity by staurosporine and other kinase inhibitors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360547

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

7 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603331

The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603331

Effect of PKC412, a selective inhibitor of protein kinase C, on lung metastasis in mice injected with B16 melanoma cells

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603331

Analytical procedure for the determination of the new antitumour drug N-benzoylstaurosporine and three potential metabolites in human plasma by reversed-phase high-performance liquid chromatography

21 January 2018

1 reference

12 December 2020

PKC412--a protein kinase inhibitor with a broad therapeutic potential

1 reference

12 December 2020

Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype

1 reference

12 December 2020

Antitumor effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6603331

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference